Physician profile
Thomas J Valente
NPI 1467416511
$967,315.96
in general payments reported to CMS, 2019-2025
33 companies · $270K in 2025
The $270K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $56K · 2021: $71K · 2022: $148K · 2023: $188K · 2024: $156K · 2025: $270K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $491K · Consulting Fee: $56K · Travel and Lodging: $37K · Food and Beverage: $26K · Honoraria: $4,400 · Education: $88.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $491,345.98 |
| Consulting Fee | $55,607.50 |
| Travel and Lodging | $37,378.15 |
| Food and Beverage | $26,251.40 |
| Honoraria | $4,400.00 |
| Education | $88.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $272,648.36 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $214,732.74 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $108,523.30 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $103,090.85 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $78,457.96 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52,149.46 | 2020-2025 | Caplyta |
| Alkermes, INC. | $51,543.05 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Allergan, INC. | $33,428.83 | 2019-2021 | |
| Abbvie INC. | $16,253.20 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $13,189.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,593.54 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $6,694.58 | 2022-2025 | Rejoyn, Rexulti, Abilify Maintena |
| Luye Pharma (USA) Ltd. | $4,401.52 | 2025 | Erzofri Extended-Release |
| Vanda Pharmaceuticals INC. | $975.14 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $500.42 | 2023-2025 | Auvelity |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $422.85 | 2019-2024 | Trintellix |
| Lundbeck LLC | $304.67 | 2019-2025 | Rexulti |
| Indivior INC. | $206.80 | 2019-2024 | Perseris |
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
| Corium, LLC | $172.38 | 2022-2024 | Azstarys, Azstarys |
| H2-Pharma, LLC | $150.00 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $150.00 | 2024 | Lumryz |
| Genentech USA, INC. | $126.51 | 2019 | |
| Supernus Pharmaceuticals, INC. | $125.75 | 2021-2024 | Qelbree, Qelbree |
| Acadia Pharmaceuticals INC | $66.94 | 2023-2025 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $57.35 | 2019-2021 | |
| Noven Therapeutics, LLC | $45.83 | 2021-2025 | Secuado |
| Merck Sharp & Dohme LLC | $34.18 | 2020-2021 | |
| Bausch Health US, LLC | $31.50 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.85 | 2025 | Jornay Pm |
| Eisai INC. | $16.40 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Valente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.